CytoAgents

CytoAgents is a clinical-stage biotechnology company focused on developing innovative pharmaceutical products to treat life-threatening symptoms associated with cytokine release syndrome (CRS), an overreaction of the immune system that causes systemic inflammation. CRS has many causes, and our mission is to develop a widely accessible treatment for multiple indications with significant unmet needs. Using a novel approach to modulate the natural immune response to multi-organ disease, CytoAgents' lead candidate, GP1681, is positioned to become a new best medical practice.